

# Hsa\_circ\_0064636 regulates voltage dependent anion channel 1/ubiquitination factor E4A through miR-326/miR-503-5 in osteosarcoma

GUOHUA YAN<sup>1\*</sup>, NANCHANG HUANG<sup>1\*</sup>, CHAOTAO CHEN<sup>1</sup>, HANJI HUANG<sup>2</sup> and JIANWEN CHENG<sup>1</sup>

<sup>1</sup>Department of Orthopedic and Traumatology Surgery, The First Affiliated Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region 530021, P.R. China; <sup>2</sup>Department of Reproductive Medicine, Guangxi Maternal and Child Health Hospital, Nanning, Guangxi Zhuang Autonomous Region 530003, P.R. China

Received October 30, 2023; Accepted March 4, 2024

DOI: 10.3892/ol.2024.14507

**Abstract.** Circular RNAs (circRNAs) are a subclass of non-coding RNAs that are important for the regulation of gene expression in eukaryotic organisms. CircRNAs exert various regulatory roles in cancer progression. However, the role of hsa\_circ\_0064636 in osteosarcoma (OS) remains poorly understood. In the present study, the expression of hsa\_circ\_0064636 in OS cell lines was measured by reverse transcription-quantitative PCR (RT-qPCR). Differentially expressed mRNAs and microRNAs (miRNA or miRs) were screened using mRNA(GSE16088) and miRNA(GSE65071) expression datasets for OS. miRNAs that can potentially interact with hsa\_circ\_0064636 were predicted using RNAhybrid, TargetScan and miRanda. Subsequently, RNAhybrid, TargetScan, miRanda, miRWalk, miRMap and miRNAMap were used for target gene prediction based on the overlapping miRNAs to construct a circ/miRNA/mRNA interaction network. Target genes were subjected to survival analysis

using PROGgeneV2, resulting in a circRNA/miRNA/mRNA interaction sub-network with prognostic significance. miRNA and circRNA in the subnetwork may also have survival significance, but relevant data are lacking and needs to be further proved. RT-qPCR demonstrated that hsa\_circ\_0064636 expression was significantly increased in OS cell lines. miR-326 and miR-503-5p were identified to be target miRNAs of hsa\_circ\_0064636. Among the target genes obtained from the miR-326 and miR-503-5p screens, ubiquitination factor E4A (UBE4A) and voltage dependent anion channel 1 (VDAC1) were respectively identified to significantly affect prognosis; only miR-326 targets UBE4A and only miR-503 targets VDAC1. To conclude, these aforementioned findings suggest that hsa\_circ\_0064636 may be involved in the development of OS by sponging miR-503-5p and miR-326 to inhibit their effects, thereby regulating the expression of VDAC1 and UBE4A.

## Introduction

Osteosarcoma (OS) is one of the most common primary bone malignancies; in 2003-2007, for most countries, OS represented 20-40% of all bone cancers (1). OS is characterized by its aggressiveness and high metastatic potential, coupled with rapid rates of progression and chemoresistance (2). Due to developments in novel resection surgical techniques and multi-drug adjuvant chemotherapeutic methods, the 5-year survival rates have improved to 70-80% by the mid-1980s (3). However, the 5-year survival rate of patients showing chemoresistance is markedly lower at <20%; patients with OS may demonstrate superior outcomes with additional therapies, including small molecule targeted agents (such as endothelin-1) (4), but these strategies are not making breakthroughs in clinical trials because of the complex biology of OS (5,6). Therefore, novel therapeutic approaches for OS, especially those with complex gene regulatory networks, are needed.

Over the past decades, new classes of non-coding RNAs (ncRNAs) have been discovered, including circular RNAs (circRNAs), microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) (3-5). During this time period, different regulatory functions associated with ncRNAs have been

*Correspondence to:* Dr Hanji Huang, Department of Reproductive Medicine, Guangxi Maternal and Child Health Hospital, 59 Vanzhu Avenue, Nanning, Guangxi Zhuang Autonomous Region 530003, P.R. China

E-mail: huanghanji@stu.gxmu.edu.cn

Professor Jianwen Cheng, Department of Orthopedic and Traumatology Surgery, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China

E-mail: 1730054162@qq.com

\*Contributed equally

*Abbreviations:* GEO, Gene Expression Omnibus; miRNA, microRNA; OS, osteosarcoma; circRNAs, circular RNAs; HR, hazard ratio; lncRNA, long non-coding RNA; RT-qPCR, reverse transcription-quantitative PCR; VDAC1, voltage dependent anion channel 1; UBE4A, ubiquitination factor E4A

*Key words:* circRNA, miRNA, osteosarcoma, VDAC1, UBE4A

revealed. In particular, ncRNAs have been reported to effectively regulate essential protein effectors of cellular function that are important for the development of OS (6-9). Knockout of MALAT1 can reduce the expression of RhoA, cell nuclear antigen and vascular growth factor (angiomin), thereby inhibiting the proliferation and invasion of human OS cells and inhibiting their metastasis (10). Amongst the various known ncRNA families, circRNAs are conserved types of special RNAs with covalent closed-loop properties, rendering them highly stable and more resistant to degradation by endonucleases (11). CircRNAs are widely found in various types of tissue and organs such as circRNA ZKSCAN1 in non-small cell lung cancer, circRNA CAMSAP1 in colorectal cancer, circRNA FBXW4 in trophoblast cell and circRNA MAN1A2 in esophageal squamous cell carcinoma (12). Circular RNAs may function similarly to regulate the activity of other miRNAs. circular RNAs may bind and sequester RNA-binding proteins or even base pair with RNAs besides microRNAs, resulting in the formation of large RNA-protein complexes (13). Previous studies have reported that circRNAs participate widely in disease development such as type2 diabetes, hypertension, spondyloarthropathies, osteoarthritis and serve important roles in cancer, such as thyroid and cervical cancer (14,15). In addition, circRNAs have been reported contribute to the onset and development of OS by controlling proliferation, invasive and metastatic ability, in addition to apoptosis, tumor cell metabolism and drug resistance (16-19). Therefore, understanding the function of circRNAs is of importance for elucidating the molecular mechanism underlying the development of OS whilst overcoming its chemoresistance potential.

In the present study, the differential expression of hsa\_circ\_0064636 in OS was assessed and its regulatory mechanism was evaluated using bioinformatic methods to determine its expression profile and prognostic significance. The aim was to provide a novel experimental basis and direction for future studies on molecular markers of OS.

## Materials and methods

**Materials and equipment.** Human normal osteoblast (hFOB1.19) and OS (HOS, SJSA-1 and MG63) cell lines were purchased from Shenzhen Haodi Huatuo Biotechnology Co., Ltd. TRIzol reagent was purchased from Invitrogen; Thermo Fisher Scientific, Inc. PrimeScript™ RT reagent Kit with gDNA Eraser and TB Green® Fast qPCR Mix were purchased from Takara Bio, Inc. A LightCycler® 96 real-time quantitative PCR instrument was purchased from Roche Diagnostics.

**Cell culture.** hFOB1.19 cells were grown in DMEM/F12 supplemented with 10% FBS with the addition of geneticin (0.3 mg/ml; all Thermo Fisher Scientific, Inc.), penicillin (100 U/ml) and streptomycin (100 U/ml). By contrast, the OS cell lines were grown in DMEM/F12 medium supplemented with 10% FBS, streptomycin (100 U/ml) and penicillin (100 U/ml). All cells were incubated at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>. Medium was replaced with fresh complete medium every 2-3 days for further incubation and when the cell density reached >90%, before the cells were passaged at a ratio of 1:3.

Table I. Primer sequences used for reverse transcription-quantitative PCR.

Gene	Sequence (5'-3')
Hsa_circ_0064636	F: GCTTCCCCTGTCTCCACATA R: ATGTCCAAAGGGTTTCAGCA
GAPDH	F: CCACTCCTCCACCTTTGAC R: ACCCTGTTGCTGTAGCCA
Ubiquitination factor E4A	F: TCCAGAGAACCTGCTACCCT R: AGTTACATCTTCAAAATGGGCTCC
Voltage dependent anion channel 1	F: GGAAGGCAGAAGATGGCTGT R: GTCCACGTGCAAGCTGATCT

F, forward; R, reverse.

**RNA extraction and reverse transcription-quantitative (RT-q) PCR.** Total cellular RNA was extracted using TRIzol and cDNA was synthesized using the miRNA First Strand cDNA Synthesis Kit (Sangon Biotech Co., Ltd.) at 25°C for 5 min, 42°C for 30 min, 85°C for 5 min. qPCR was performed using the SYBR green PCR mix (TB Green® Fast qPCR Mix) and divergent primers from hsa\_circ\_0064636 were used with reaction conditions as follows: Pre-denaturation at 95°C for 10 min, followed by denaturation at 95°C for 15 sec and annealing at 60°C for 30 sec for 45 cycles. The expression levels of GAPDH (circRNA) and U6 (miRNA) were used as internal controls. The relative expression of the screened genes was calculated using the 2<sup>-ΔΔC<sub>q</sub></sup> method (20). The primers used in the present study are presented in Table I; primer sequence for U6 is not available.

**Construction of the circRNA/miRNA/mRNA network.** miRNAs interacting with hsa\_circ\_0064636 were predicted using the circRNA target miRNA prediction tools RNAhybrid (21), TargetScan (22) and miRanda (23) before being subjected to intersection analysis to screen out miRNAs that were commonly identified by the three prediction tools. For miRNA targeting, gene prediction tools, including RNAhybrid, TargetScan, miRanda, miRWalk (24), miRMap (25) and miRMAP (26) were used to predict target genes for the intersecting miRNAs. These were compared with the screened miRNAs, before seven (six database prediction ensembles and a variance analysis) intersects from the differentially expressed miRNAs were finally identified. The selected circRNA-miRNAs and miRNA-mRNAs were then used to construct and visualize the regulatory network of circRNA/miRNA/mRNA using Cytoscape 3.8.0 (cytoscape.org/). Venn diagrams of predicted miRNAs or target genes were plotted using the R (version 4.2.3) package 'Venn' (version 1.11).

**Analysis of the differential expression of miRNAs.** The GSE65071 (9 normal samples from healthy individuals, 14 OS samples) and GSE16088 (9 normal samples, 14 OS samples) expression datasets and RNA-seq were downloaded from the Gene Expression Omnibus (GEO; <https://www.ncbi.nlm.nih>).




Figure 1. Hsa\_circ\_006463 expression validation and prediction of differentially expressed miRNAs. (A) Expression of hsa\_circ\_006463 in osteosarcoma cell lines. \*\*P<0.01, \*\*\*P<0.001. Volcano plots of (B) Differential miRNA expression, with the positions of miR-326 and miR-503-5p labeled and (C) Differential mRNA expression with the positions of VDAC1 and UBE4A labeled. (D) Venn diagram of hsa\_circ\_006463 target miRNAs predicted using the TargetScan, miRanda and RNAhybrid databases, with the two most commonly miRNAs labeled on the right side of the figure. DEG, differentially expressed gene; miR, microRNA.

gov/geo/) database and the ‘affy’ (to read gene expression microarray data from affymetix) package (version 3.18) was used. The ‘Limma’ (version 3.54.2).package was used to identify differentially expressed genes between normal and tumor samples with  $\text{log}_2[\text{fold change (FC)}]>1$  and adjusted P<0.05 set as the significance criteria. The differentially expressed genes were plotted using the ‘ggplot2’ (version 3.4.3) package and a volcano plot was produced.

**Survival analysis.** PROGgeneV2 (progttools.net/gene/filter.php) (27) was used along with aforementioned GEO data to investigate the prognostic significance of genes. The target genes obtained from the aforementioned intersection) were input into a PROGgeneV2 before the dataset for OS was selected and the overall survival map was constructed based on the median expression of a given gene for classification into high and low expression groups for plotting Kaplan-Meier curves with PROGgeneV2. ‘PROGeneV2’ was used for hypothesis testing using the ‘Survival’ (version 3.5.3) package in R (version 4.2.3). Statistical analysis was performed using the log-rank test and the threshold for a meaningful survival

prognosis was set as P<0.05. Based on the survival analysis, a new circRNA/miRNA/mRNA visual regulatory sub-network was obtained using Cytoscape (cytoscape.org/) 3.8.0.

**Statistical analysis.** GraphPad Prism 8 (Dotmatics) software was used to statistically analyze the experimental data. The test data were normally distributed. Data are presented as the means  $\pm$  SD of three independent experiments. P<0.05 was considered to indicate a statistically significant difference. Statistical comparison between groups was evaluated using one-way ANOVA with the Dunnett’s post hoc test.

**Results**

**Analysis of differentially expressed miRNAs and mRNAs in OS.** The expression of hsa\_circ\_0064636 was found to be significantly higher in the three human OS cell lines compared with that in the hFOB1.19 osteoblasts (Fig. 1A). A total of 114 miRNAs were shown to be upregulated, whilst 117 were downregulated in OS (compared with normal group) based on the miRNA (GSE65071) expression profile data. Differentially

expressed miRNAs were visualized using a volcano plot (Fig. 1B). Differential analysis of the mRNA expression (GSE16088) spectrum data identified 716 mRNAs that were downregulated and 1,924 mRNAs that were upregulated (OS versus normal). Differentially expressed mRNAs were visualized using a volcano plot (Fig. 1C).

*Hsa\_circ\_006463 targets the predicted miRNA.* To assess the regulatory mechanism of hsa\_circ\_006463 in OS, miRNAs targeted by hsa\_circ\_006463 were predicted using three databases. TargetScan, miRanda and RNAhybrid predicted 498, 965 and 226 target miRNAs, respectively. Differential expression analysis yielded 88 target (downregulated) miRNAs. Intersecting miRNAs targeted by hsa\_circ\_006463 according to all four different databases used were found to be miR-326 and miR-503-5p (Fig. 1D).

*Prediction and analysis of miR-326 and miR-503-5p targets.* The regulatory action of hsa-miR-326 and miR-503-5p in OS was then assessed based on the possible binding of target mRNAs. miR-326 target genes were predicted using the miRWalk, miRanda, miRMap, miRNAMap, RNAhybrid and TargetScan databases, with 5,071, 3,364, 6,616, 6,716, 16,373 and 4,830 target genes identified, respectively. Intersection with 1,924 upregulated differential genes identified 31 target genes using Venn diagram analysis (Fig. 2A). Target genes of miR-503-5p were also analyzed using the miRWalk, miRanda, miRMap, miRNAMap, RNAhybrid and TargetScan, with 2,034, 844, 6,692, 1,496, 12,416 and 2,196 target genes identified, respectively. These were subjected to intersection analysis with 1,924 differentially upregulated genes and 31 target genes were identified (Fig. 2B).

*Construction of the circRNA/miRNA/mRNA network.* In total, six databases were used to predict binding targets of miR-326 and miR-503-5p, yielded 31 and 6 target gene relationships, respectively. These were used to construct relationship networks (Fig. 3). Hsa\_circ\_0064636 was therefore predicted to target miR-326 and miR-503-5p. The potential target genes of miR-326 included TNC, HNRNPA2B1, ATXN1, DPYSL2, RGS3, ubiquitination factor E4A (UBE4A), MRC2, PSMC1, FOXO3, SRRM1, SAMD4A, MYO1D, ADAM17, PDIA4, VGLL4, FYN, NFATC3, VCL, SPAG9, MED13L, RAI14, MYOF, NDEL1, TUBB, ALPL, USP11, CEP350, LSM1, GOLPH3, C9orf3 and CUX1 (31 target genes). By contrast, miR-503-5p target genes were PSMD7, INSR, PTPN12, TCF7L2, voltage dependent anion channel 1 (VDAC1) and TPM1 (6 target genes).

*Survival analysis.* Survival curves for overall survival were plotted for 31 of the 37 target genes, as shown in Table II. For survival analysis of the target genes, only two differences were found significant, namely UBE4A and VDAC1 (Fig. 4). This implies that patients with osteosarcoma have poorer prognostic survival when UBE4A and VDAC1 are highly expressed. According to Fig. 2, UBE4A was a target gene of miR-326 whereas VDAC1 was a target gene of miR-503-5p.

*CircRNA/miRNA/mRNA network has prognostic significance in OS.* Based on the original circRNA/miRNA/mRNA




Figure 2. Target gene prediction and differential gene expression of miRNAs. Venn diagram showing the intersection of data from six databases and differentially expressed genes (OS compared to normal group) to predict binding target genes for (A) miR-326 and (B) miR-503-5p. The names of the target mRNAs are shown on the right. DEG, differentially expressed gene; UBE4A, ubiquitination factor E4A; VDAC1, voltage dependent anion channel 1; miR, microRNA.

competing endogenous RNA interaction network, though RAI14 was significant in the survival analysis, RAI14 is highly expressed in osteosarcoma compared with normal group, but survival analysis of RAI14 low expression group has better survival prognosis. Thus only two target genes with prognostic significance for survival (UBE4A and VDAC1) were retained before a new sub-network with prognostic implications was created (Fig. 5A).

*Validation of differential miRNA and mRNA expression in OS cell lines.* Differential expression of hsa\_circ\_0064636 was next assessed using RT-qPCR in human (HOS, SJSA-1, MG63) OS cell lines and the human osteoblast (hFOB1.19) cell line. The expression of hsa\_circ\_0064636 was found to be significantly higher in the human OS cell line compared with that in the osteoblast cell line (Fig. 1A). The expression levels of hsa-miR-326 (Fig. 5B) and hsa-miR-503 (Fig. 5C) were significantly lower in OS cell lines compared with those in the osteoblast cell line. UBE4A (Fig. 5D) and VDAC1 (Fig. 5E) expression were found to be significantly increased in the OS cell lines compared with that in the human osteoblast cell line. A schematic representation of the target gene and corresponding miRNA binding site are presented in Fig. 5F.






Figure 3. CircRNA/miRNA/mRNA competing endogenous RNA regulatory network starting with hsa\_circ\_0064636. The red circle represents circRNA, blue triangles represent miRNAs and yellow squares represent mRNAs. CircRNA, circular RNA; miR, microRNA.

**Discussion**

OS is one of the most common malignancies in the bone, Treatment of OS remains a major challenge. Existing treatment options for OS include as surgery and chemotherapy, but the prognosis of patients remains unsatisfactory (28). Although four genes [BRCA1, mutS homolog 2, CCND1 (cyclin D1) and ITGA5 (integrin subunit alpha 5)] have been documented to associate with the development and progression of OS, the focus has been only on protein-coding genes or miRNAs (29). In addition, molecular mechanisms underlying the development and progression of OS remain poorly understood. A number of ncRNAs have been reported to be important in the development of OS (30-33). The lncRNA TMPO-AS1 was previously found to decreases miR-199a-5p/WNT7B(elevated) axis, thereby functioning as a ceRNA that promotes tumorigenesis in OS (34). In addition, miR-1236-3p overexpression inhibits cell proliferation and induces apoptosis by targeting Krueppel-like factor 8 (35).

Unlike other ncRNAs, including lncRNAs and miRNAs, circRNAs are highly conserved and stable in mammalian cells. These properties render them potentially ideal biomarkers and therapeutic targets (36). Previous studies have reported the important role of circRNAs in different processes, including tumorigenesis, development and metastasis, of tumors such as gastric (37), colorectal (38), lung (39) and cervical (40) cancer. Circ-transcriptional Adaptor 2A was previously found to be differentially expressed between OS cell lines (HOS, 143B,U2OS,SJSA-1,MG63) and corresponding non-cancer cell lines (HEK-293 and hFOB1.19), with higher expression in OS (41). In the present study, the significantly upregulated expression of hsa\_circ\_0064636 in OS cell lines compared with normal tissue cell lines was found before a regulatory

network of its miRNA targets and downstream mRNA targets was constructed.

In the present study, miR-326 and miR-503-5p were predicted to be the target miRNAs of hsa\_circ\_0064636 using multiple databases, yielding circRNA/miRNA interactions. miR-326 and miR-503-5 were identified from the GSE65071 dataset and were downregulated in OS samples compared with normal samples, before their expression in OS samples was verified. Here, hsa\_circ\_0064636 was found to be significantly upregulated in OS, miR-326 to promote cervical cancer progression through up-regulation of ELK1 (42). The overexpression of miR-326 can lead to the inhibition of proliferation and invasion, whilst inducing apoptosis and autophagy in cervical cancer cells (42). In addition, miR-326 expression was previously found to be significantly downregulated in prostate cancer (43), which associated with the prognoses of these patients. By contrast, miR-503-5p has been reported to inhibit tumorigenesis, angiogenesis and lymphangiogenesis in colon cancer through the direct inhibition of VEGF-A expression (44). In hepatocellular carcinoma, miR-503-5p was documented to regulate epithelial-to-mesenchymal transition, metastasis and prognosis through the inhibition of WEE1 (45). miR-326 and miR-503-5p are key for the suppression of numerous tumors such as prostatic carcinoma and colon cancer (44,46), where their expression is low in certain cancers such as miR-326 is low expressed in lung adenocarcinoma and miR-503-5p is low expressed in colon cancer. Therefore, hsa\_circ\_0064636 may promote OS development by suppressing the expression of miR-326 and miR-503-5p. To the best of our knowledge, studies on miR-326 and miR-503-5p in OS are lacking.

The present study performed miRNA prediction using miRWalk, miRanda, miRMap, miRNAMap, RNAhybrid and TargetScan. Significantly differentially expressed genes in

Table II. Target gene survival analysis.

Gene	miRNA	Hazard ratio	LCI (95%)	UCI (95%)	P-value
TNC	hsa-miR-326	0.80	0.59	1.09	0.16087
ATXN1	hsa-miR-326	1.06	0.45	2.51	0.89614
DPYSL2	hsa-miR-326	0.72	0.31	1.66	0.44617
RGS3	hsa-miR-326	0.59	0.21	1.61	0.30120
UBE4A	hsa-miR-326	1.60	1.00	2.57	0.04894
MRC2	hsa-miR-326	0.81	0.38	1.73	0.59453
PSMC1	hsa-miR-326	0.38	0.10	1.40	0.14712
SRRM1	hsa-miR-326	1.11	0.35	3.51	0.85323
SAMD4A	hsa-miR-326	0.75	0.25	2.28	0.61097
MYO1D	hsa-miR-326	0.76	0.4	1.45	0.40852
ADAM17	hsa-miR-326	0.4	0.06	2.86	0.36201
PDIA4	hsa-miR-326	0.81	0.38	1.74	0.58828
VGLL4	hsa-miR-326	1.03	0.46	2.27	0.95088
FYN	hsa-miR-326	1.66	0.7	3.95	0.25158
NFATC3	hsa-miR-326	4.94	0.76	32.03	0.09380
VCL	hsa-miR-326	0.60	0.29	1.24	0.16888
SPAG9	hsa-miR-326	0.45	0.18	1.17	0.10087
RAI14	hsa-miR-326	0.33	0.16	0.68	0.00261
NDEL1	hsa-miR-326	0.81	0.35	1.9	0.62756
TUBB	hsa-miR-326	1.59	0.92	2.78	0.09927
ALPL	hsa-miR-326	1.07	0.83	1.39	0.59196
USP11	hsa-miR-326	0.5	0.18	1.38	0.18324
CEP350	hsa-miR-326	0.88	0.35	2.21	0.78379
LSM1	hsa-miR-326	1.58	0.78	3.22	0.20742
GOLPH3	hsa-miR-326	1.54	0.94	2.5	0.08360
PSMD7	hsa-miR-503-5p	0.70	0.32	1.54	0.37880
INSR	hsa-miR-503-5p	0.13	0.01	1.79	0.12555
PTPN12	hsa-miR-503-5p	1.62	0.89	2.94	0.11362
TCF7L2	hsa-miR-503-5p	3.99	0.79	20.11	0.09396
VDAC1	hsa-miR-503-5p	4.09	1.26	13.29	0.01919
TPM1	hsa-miR-503-5p	0.73	0.47	1.16	0.185767
HNRNPA2B1	hsa-miR-326	-	-	-	-
FOXO3	hsa-miR-326	-	-	-	-
MYOF	hsa-miR-326	-	-	-	-
C9orf3	hsa-miR-326	-	-	-	-
CUX1	hsa-miR-326	-	-	-	-

UBE4A, ubiquitination factor E4A; VDAC1, voltage dependent anion channel 1; miR or miRNA, microRNA; LCI, lower confidence interval; UCI, upper confidence interval; -, data not available.

OS were used to screen for potential target genes of miR-326 and miR-503-5p to obtain a circRNA/miRNA/mRNA ceRNA interaction network. Subsequently, mRNAs with prognostic significance were also screened to obtain a circRNA/miRNA/mRNA regulatory sub-network. UBE4A was identified to be a potential direct target of miR-326 whereas VDAC1 was found to be a potential direct target of miR-503-5p. A significant difference in prognosis between UBE4A and VDAC1 was confirmed in a survival analysis of OS patients. The results of survival analysis showed that the prognosis of patients was significantly worse in the high

UBE4A and VDAC1 expression group compared with that in the low expression group.

UBE4A belongs to the U-box ubiquitin ligase class of enzymes. The encoded protein is involved in polyubiquitin chain assembly and regulates chromosome condensation and polyubiquitination segregation through securing (47). Auto-antibodies against the encoded protein (recombinant C-terminal UBE4A Protein) are potential markers for scleroderma and Crohn's disease (47,48). UBE4A was found to be significantly upregulated in ovarian plasmatic cystic carcinoma compared with the adjacent normal tissues. The VDAC1 channel forms a major




Figure 4. Survival curves of target genes. Survival curves were plotted for (A) VDAC1 and (B) UBE4A based on Kaplan-Meier analysis using the 'PROGeneV2' online platform. HR, hazard ratio; UBE4A, ubiquitination factor E4A; VDAC1, voltage dependent anion channel 1.




Figure 5. CircRNA/miRNA/mRNA competing endogenous RNA regulatory network based on the target genes with prognostic significance. (A) Red circles represent circRNAs, Blue triangles represent miRNAs and yellow squares represent mRNAs. Expression of (B) hsa-miR-326, (C) hsa-miR-503-5p, (D) UBE4A and (E) VDAC1 in osteosarcoma and normal osteoblast cell lines. \*P<0.05, \*\*P<0.01, \*\*\*P<0.001 vs. hFOB1.19. (F) Schematic representation of target genes and miRNA binding sites. CircRNA, circular RNA; UBE4A, ubiquitination factor E4A; VDAC1, voltage dependent anion channel 1; miRNA, microRNA.

component of the outer mitochondrial membrane (49). VDAC1 is expressed in all compartments, including mitochondria, plasma membrane. This protein regulates major metabolic and energetic functions in the cell, including Ca<sup>2+</sup> homeostasis, oxidative stress and mitochondria-mediated apoptosis (50,51). VDAC1 may be associated with the destruction of nerve cells, where its overexpression triggers cell death (52). Furthermore, VDAC1 was found to be a tumor promoter in cervical cancer, where its knockdown in cervical cancer cell line S12 increased the rate of apoptosis in a manner that was partially reversed by the overexpression of VDAC1 (53).

In the present study, RT-qPCR analysis demonstrated that hsa\_circ\_00063636, VDAC1 and UBE4A were highly expressed in OS cell lines, whereas miR-326 and miR-503-5p expression was significantly lower in OS cell lines. These results were consistent with those of the bioinformatics analysis. A limitation of the present study is that the regulatory network was not validated experimentally and further investigations are required such as experimentally verifying miRNA binding to mRNAs. In the present study, bioinformatic methods are used to predict potential regulatory networks, with emphasis on discovering new targets and potential networks. However, further verification of the regulation between miRNA and mRNA is required.

In conclusion, a sub-regulatory network of hsa\_circ\_0064636-miR-326/miR-503-5p-UBE4A/VDAC1 was identified with significance for survival prognosis. RT-qPCR experiments demonstrated that hsa\_circ\_0064636, UBE4A and VDAC1 were significantly and differentially overexpressed in OS cell lines, whilst miR-326 and miR-503-5p were downregulated. It was hypothesized that hsa\_circ\_0064636 may be involved in the development of OS by acting as a sponge, thereby suppressing miR-326 and miR-503-5p to facilitate the upregulation of VDAC1 and UBE4A.

### Acknowledgements

Not applicable.

### Funding

The present study received financial support from the National Natural Science Foundation of China (grant no. 81960400).

### Availability of data and materials

The data generated in the present study may be requested from the corresponding author.

### Authors' contributions

GHY and NCH confirm the authenticity of all the raw data. GHY and NCH designed the study and drafted the manuscript. CTC, JWC and HJH interpreted data. JWC and HJH revised the manuscript. All authors have read and approved the final version of the manuscript.

### Ethics approval and consent to participate

Not applicable.

### Patient consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### References

1. Valery PC, Laversanne M and Bray F: Bone cancer incidence by morphological subtype: A global assessment. *Cancer Causes Control* 26: 1127-1139, 2015.
2. Saraf AJ, Fenger JM and Roberts RD: Osteosarcoma: Accelerating progress makes for a hopeful future. *Front Oncol* 8: 4, 2018.
3. Chou AJ and Gorlick R: Chemotherapy resistance in osteosarcoma: Current challenges and future directions. *Expert Rev Anticancer Ther* 6: 1075-1085, 2006.
4. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, *et al*: Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. *Clin Cancer Res* 9: 2587-2597, 2003.
5. Otoukesh B, Boddouhi B, Moghtadaei M, Kaghazian P and Kaghazian M: Novel molecular insights and new therapeutic strategies in osteosarcoma. *Cancer Cell Int* 18: 158, 2018.
6. Bishop MW, Janeway KA and Gorlick R: Future directions in the treatment of osteosarcoma. *Curr Opin Pediatr* 28: 26-33, 2016.
7. Nemeth K, Bayraktar R, Ferracin M and Calin GA: Non-coding RNAs in disease: From mechanisms to therapeutics. *Nat Rev Genet* 25: 211-232, 2024.
8. Wang K, Jiang W, Cheng C, Li Y and Tu M: Pathological and therapeutic aspects of long noncoding RNAs in osteosarcoma. *Anticancer Agents Med Chem* 13: 10.2174/1871520617666170213122442, 2017.
9. Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, *et al*: miRNA signatures associate with pathogenesis and progression of osteosarcoma. *Cancer Res* 72: 1865-1877, 2012.
10. Cai X, Liu Y, Yang W, Xia Y, Yang C, Yang S and Liu X: Long noncoding RNA MALAT1 as a potential therapeutic target in osteosarcoma. *J Orthop Res* 34: 932-941, 2016.
11. Liu CX, Li X, Nan F, Jiang S, Gao X, Guo SK, Xue W, Cui Y, Dong K, Ding H, *et al*: Structure and degradation of circular RNAs regulate PKR activation in innate immunity. *Cell* 177: 865-880.e21, 2019.
12. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, *et al*: Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature* 495: 333-338, 2013.
13. Das A, Sinha T, Shyamal S and Panda AC: Emerging role of circular RNA-protein interactions. *Noncoding RNA* 7: 48, 2021.
14. Wilusz JE and Sharp PA: Molecular biology. A circuitous route to noncoding RNA. *Science* 340: 440-441, 2013.
15. Yang F, Chen Y, Xue Z, Lv Y, Shen L, Li K, Zheng P, Pan P, Feng T, Jin L and Yao Y: High-throughput sequencing and exploration of the lncRNA-circRNA-miRNA-mRNA network in type 2 diabetes mellitus. *Biomed Res Int* 2020: 8162524, 2020.
16. Trang NTN, Lai CY, Tsai HC, Huang YL, Liu SC, Tsai CH, Fong YC, Tzeng HE and Tang CH: Apelin promotes osteosarcoma metastasis by upregulating PLOD2 expression via the Hippo signaling pathway and hsa\_circ\_0000004/miR-1303 axis. *Int J Biol Sci* 19: 412-425, 2023.
17. Yu L, Zhu H, Wang Z, Huang J, Zhu Y, Fan G, Wang Y, Chen X and Zhou G: Circular RNA circFIRRE drives osteosarcoma progression and metastasis through tumorigenic-angiogenic coupling. *Mol Cancer* 21: 167, 2022.
18. Zhang M, Yu GY, Liu G and Liu WD: Circular RNA circ\_0002137 regulated the progression of osteosarcoma through regulating miR-433-3p/IGF1R axis. *J Cell Mol Med* 26: 1806-1816, 2022.
19. Liu Y, Qiu G, Luo Y, Li S, Xu Y, Zhang Y, Hu J, Li P, Pan H and Wang Y: Circular RNA ROCK1, a novel circRNA, suppresses osteosarcoma proliferation and migration via altering the miR-532-5p/PTEN axis. *Exp Mol Med* 54: 1024-1037, 2022.



20. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
21. Rehmsmeier M, Steffen P, Höchsmann M and Giegerich R: Fast and effective prediction of microRNA/target duplexes. *RNA* 10: 1507-1517, 2004.
22. Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. *Elife* 4: e05005, 2015.
23. Riffo-Campos ÁL, Riquelme I and Brebi-Mieville P: Tools for sequence-based miRNA target prediction: What to choose? *Int J Mol Sci* 17: 1987, 2016.
24. Dweep H, Sticht C, Pandey P and Gretz N: miRWalk-database: Prediction of possible miRNA binding sites by 'walking' the genes of three genomes. *J Biomed Inform* 44: 839-847, 2011.
25. Vejnar CE, Blum M and Zdobnov EM: miRmap web: Comprehensive microRNA target prediction online. *Nucleic Acids Res* 41: W165-W168, 2013.
26. Hsu SD, Chu CH, Tsou AP, Chen SJ, Chen HC, Hsu PW, Wong YH, Chen YH, Chen GH and Huang HD: miRNAmap 2.0: Genomic maps of microRNAs in metazoan genomes. *Nucleic Acids Res* 36: D165-D169, 2008.
27. Goswami CP and Nakshatri H: PROGgeneV2: Enhancements on the existing database. *BMC Cancer* 14: 970, 2014.
28. Gillespie EF, Yang JC, Mathis NJ, Marine CB, White C, Zhang Z, Barker CA, Kotecha R, McIntosh A, Vaynrub M, *et al*: Prophylactic radiation therapy versus standard of care for patients with high-risk asymptomatic bone metastases: A multicenter, randomized phase II clinical trial. *J Clin Oncol* 42: 38-46, 2024.
29. Yang J and Wang N: Analysis of the molecular mechanism of osteosarcoma using a bioinformatics approach. *Oncol Lett* 12: 3075-3080, 2016.
30. Wang J, Liu S, Shi J, Li J, Wang S, Liu H, Zhao S, Duan K, Pan X and Yi Z: The role of miRNA in the diagnosis, prognosis, and treatment of osteosarcoma. *Cancer Biother Radiopharm* 34: 605-613, 2019.
31. Wang JY, Yang Y, Ma Y, Wang F, Xue A, Zhu J, Yang H, Chen Q, Chen M, Ye L, *et al*: Potential regulatory role of lncRNA-miRNA-mRNA axis in osteosarcoma. *Biomed Pharmacother* 121: 109627, 2020.
32. Hei R, Chen J, Zhang X, Bian H, Chen C, Wu X, Han T, Zhang Y, Gu J, Lu Y and Zheng Q: CircNRI1 acts as a sponge of miR-1200 to suppress osteosarcoma progression via upregulation of MIA2. *Am J Cancer Res* 12: 2833-2849, 2022.
33. Qin S, Wang Y, Ma C and Lv Q: Competitive endogenous network of circRNA, lncRNA, and miRNA in osteosarcoma chemoresistance. *Eur J Med Res* 28: 354, 2023.
34. Cui H and Zhao J: lncRNA TMPO-AS1 serves as a ceRNA to promote osteosarcoma tumorigenesis by regulating miR-199a-5p/WNT7B axis. *J Cell Biochem* 121: 2284-2293, 2020.
35. Sun Y, Cao L, Lin JT, Yuan Y, Cao ZL and Jia JD: Upregulated miRNA-1236-3p in osteosarcoma inhibits cell proliferation and induces apoptosis via targeting KLF8. *Eur Rev Med Pharmacol Sci* 23: 6053-6061, 2019.
36. Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF and Sharpless NE: Circular RNAs are abundant, conserved, and associated with ALU repeats. *RNA* 19: 141-157, 2013.
37. Li R, Jiang J, Shi H, Qian H, Zhang X and Xu W: CircRNA: A rising star in gastric cancer. *Cell Mol Life Sci* 77: 1661-1680, 2020.
38. Ju HQ, Zhao Q, Wang F, Lan P, Wang Z, Zuo ZX, Wu QN, Fan XJ, Mo HY, Chen L, *et al*: A circRNA signature predicts postoperative recurrence in stage II/III colon cancer. *EMBO Mol Med* 11: e10168, 2019.
39. Zong L, Sun Q, Zhang H, Chen Z, Deng Y, Li D and Zhang L: Increased expression of circRNA\_102231 in lung cancer and its clinical significance. *Biomed Pharmacother* 102: 639-644, 2018.
40. Song T, Xu A, Zhang Z, Gao F, Zhao L, Chen X, Gao J and Kong X: CircRNA hsa\_circRNA\_101996 increases cervical cancer proliferation and invasion through activating TPX2 expression by restraining miR-8075. *J Cell Physiol* 234: 14296-14305, 2019.
41. Wu Y, Xie Z, Chen J, Ni W, Ma Y, Huang K, Wang G, Wang J, Ma J, *et al*: Circular RNA circTADA2A promotes osteosarcoma progression and metastasis by sponging miR-203a-3p and regulating CREB3 expression. *Mol Cancer* 18: 73, 2019.
42. Tang Q, Chen Z, Zhao L and Xu H: Circular RNA hsa\_circ\_0000515 acts as a miR-326 sponge to promote cervical cancer progression through up-regulation of ELK1. *Aging (Albany NY)* 11: 9982-9999, 2019.
43. Moya L, Meijer J, Schubert S, Matin F and Batra J: Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 expression as biomarker for prostate cancer diagnosis. *Int J Mol Sci* 20: 1154, 2019.
44. Wei L, Sun C, Zhang Y, Han N and Sun S: miR-503-5p inhibits colon cancer tumorigenesis, angiogenesis, and lymphangiogenesis by directly downregulating VEGF-A. *Gene Ther* 29: 28-40, 2022.
45. Jiang SP and Li ZR: MiR-503-5p regulates cell epithelial-to-mesenchymal transition, metastasis and prognosis of hepatocellular carcinoma through inhibiting WEE1. *Eur Rev Med Pharmacol Sci* 23: 2028-2037, 2019.
46. Liang X, Li Z, Men Q, Li Y, Li H and Chong T: miR-326 functions as a tumor suppressor in human prostatic carcinoma by targeting Mucin1. *Biomed Pharmacother* 108: 574-583, 2018.
47. Contino G, Amati F, Pucci S, Pontieri E, Pichiorri F, Novelli A, Botta A, Mango R, Nardone AM, Sangiuolo FC, *et al*: Expression analysis of the gene encoding for the U-box-type ubiquitin ligase UBE4A in human tissues. *Gene* 328: 69-74, 2004.
48. Sakiyama T, Fujita H and Tsubouchi H: Autoantibodies against ubiquitination factor E4A (UBE4A) are associated with severity of Crohn's disease. *Inflamm Bowel Dis* 14: 310-317, 2008.
49. Yi X, Xiao F, Zhong X, Duan Y, Liu K and Zhong C: A Ca<sup>2+</sup> chelator ameliorates chromium (VI)-induced hepatocyte L-02 injury via down-regulation of voltage-Dependent anion channel 1 (VDAC1) expression. *Environ Toxicol Pharmacol* 49: 27-33, 2017.
50. Liu C, Li H, Duan W, Duan Y, Yu Q, Zhang T, Sun YP, Li YY, Liu YS and Xu SC: MCU upregulation overactivates mitophagy by promoting VDAC1 dimerization and ubiquitination in the hepatotoxicity of cadmium. *Adv Sci (Weinh)* 10: 2203869, 2023.
51. Shoshan-Barmatz V, De Pinto V, Zweckstetter M, Raviv Z, Keinan N and Arbel N: VDAC, a multi-functional mitochondrial protein regulating cell life and death. *Mol Aspects Med* 31: 227-285, 2010.
52. Shoshan-Barmatz V, Nahon-Crystal E, Shteiinfer-Kuzmine A and Gupta R: VDAC1, mitochondrial dysfunction, and Alzheimer's disease. *Pharmacol Res* 131: 87-101, 2018.
53. Zhang C, Ding W, Liu Y, Hu Z, Zhu D, Wang X, Yu L, Wang L, Shen H, Zhang W, *et al*: Proteomics-based identification of VDAC1 as a tumor promoter in cervical carcinoma. *Oncotarget* 7: 52317-52328, 2016.



Copyright © 2024 Yan et al. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.